These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 32433778)

  • 1. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
    Thibaud S; Tremblay D; Bhalla S; Zimmerman B; Sigel K; Gabrilove J
    Br J Haematol; 2020 Jul; 190(2):e73-e76. PubMed ID: 32433778
    [No Abstract]   [Full Text] [Related]  

  • 2. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
    Treon SP; Castillo JJ; Skarbnik AP; Soumerai JD; Ghobrial IM; Guerrera ML; Meid K; Yang G
    Blood; 2020 May; 135(21):1912-1915. PubMed ID: 32302379
    [No Abstract]   [Full Text] [Related]  

  • 3. BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
    Chong EA; Roeker LE; Shadman M; Davids MS; Schuster SJ; Mato AR
    Clin Cancer Res; 2020 Jul; 26(14):3514-3516. PubMed ID: 32345646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
    Baumann T; Delgado J; Montserrat E
    Leukemia; 2020 Jul; 34(7):1954-1956. PubMed ID: 32433507
    [No Abstract]   [Full Text] [Related]  

  • 6. Bringing hospital care closer to patients amidst COVID-19.
    Cordoba R
    Lancet Haematol; 2020 Sep; 7(9):e637. PubMed ID: 32853582
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
    Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernández-Rivas JÁ; Miras F; Fernández Escalada N; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; López-Jiménez J; Naya D; Garcia-Marco JA; Skånland SS; Cordoba R; Eyre TA
    Blood; 2020 Sep; 136(10):1134-1143. PubMed ID: 32688395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
    Scarfò L; Chatzikonstantinou T; Rigolin GM; Quaresmini G; Motta M; Vitale C; Garcia-Marco JA; Hernández-Rivas JÁ; Mirás F; Baile M; Marquet J; Niemann CU; Reda G; Munir T; Gimeno E; Marchetti M; Quaglia FM; Varettoni M; Delgado J; Iyengar S; Janssens A; Marasca R; Ferrari A; Cuéllar-García C; Itchaki G; Špaček M; De Paoli L; Laurenti L; Levin MD; Lista E; Mauro FR; Šimkovič M; Van Der Spek E; Vandenberghe E; Trentin L; Wasik-Szczepanek E; Ruchlemer R; Bron D; De Paolis MR; Del Poeta G; Farina L; Foglietta M; Gentile M; Herishanu Y; Herold T; Jaksic O; Kater AP; Kersting S; Malerba L; Orsucci L; Popov VM; Sportoletti P; Yassin M; Pocali B; Barna G; Chiarenza A; Dos Santos G; Nikitin E; Andres M; Dimou M; Doubek M; Enrico A; Hakobyan Y; Kalashnikova O; Ortiz Pareja M; Papaioannou M; Rossi D; Shah N; Shrestha A; Stanca O; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Coscia M; Stamatopoulos K; Rossi G; Rambaldi A; Montserrat E; Foà R; Cuneo A; Ghia P
    Leukemia; 2020 Sep; 34(9):2354-2363. PubMed ID: 32647324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
    Roschewski M; Lionakis MS; Sharman JP; Roswarski J; Goy A; Monticelli MA; Roshon M; Wrzesinski SH; Desai JV; Zarakas MA; Collen J; Rose K; Hamdy A; Izumi R; Wright GW; Chung KK; Baselga J; Staudt LM; Wilson WH
    Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32503877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.
    Busygina K; Jamasbi J; Seiler T; Deckmyn H; Weber C; Brandl R; Lorenz R; Siess W
    Blood; 2018 Jun; 131(24):2605-2616. PubMed ID: 29559479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic.
    Sehn LH; Kuruvilla P; Christofides A; Stakiw J
    Curr Oncol; 2020 Jun; 27(3):e332-e335. PubMed ID: 32669941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
    Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
    Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
    Sun C; Nierman P; Kendall EK; Cheung J; Gulrajani M; Herman SEM; Pleyer C; Ahn IE; Stetler-Stevenson M; Yuan CM; Maric I; Gaglione EM; Harris HM; Pittaluga S; Wang MH; Patel P; Farooqui MZH; Izumi R; Hamdy A; Covey T; Wiestner A
    Blood; 2020 Jul; 136(1):93-105. PubMed ID: 32202637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
    Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
    Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Jain P; Kanagal-Shamanna R; San Lucas FA; Nastoupil L; Romaguera J; Fayad L; Oki Y; Westin JR; Medeiros LJ; Wang M; Fowler N
    Br J Haematol; 2018 Sep; 182(5):718-723. PubMed ID: 28771675
    [No Abstract]   [Full Text] [Related]  

  • 20. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Danilov AV; Persky DO
    Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.